Drug intelligence / Profile preview

CT-P66

Development stage: Discontinued
Lead developer: Celltrion
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Inhalation

Overview

CT-P66 is a monoclonal antibody developed by Celltrion. It was designed as part of a combination therapy with CT-P63 to target the SARS-CoV-2 spike protein, specifically the receptor binding domain, for the treatment of COVID-19 infection. The drug acts as an inhibitor of the coronavirus spike glycoprotein, aiming to neutralize the virus and prevent its entry into host cells. The primary modality is inhaled administration for symptomatic patients with COVID-19 who do not require supplemental oxygen. Development reached Phase 3 clinical trials but has since been discontinued[1][2][3][4].

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on CT-P66.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-P66.

Explore the full profile